Microbial Transplant Therapy for Kidney Stones

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Park City Hospital, Park City, UT
Kidney Stones+3 More
Microbial Transplant Therapy - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to measure the impact of Microbial Transplant Therapy (MTT) on 24-hour urine parameters in recurrent hypercalciuric and hyperoxaluric kidney stone formers.

Eligible Conditions

  • Kidney Stones

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Kidney Stones

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: Prior to fecal transplant (baseline)

Day 30
Proportion of participants with an adverse event
Week 3
Changes in 24 hour urinary calcium concentration
Week 3
Changes in 24 hour urinary oxalate concentration
Prior to fecal transplant (baseline)
Metagenomic changes to subject microbiota pre-MTT
Week 4
Metagenomic changes to subject microbiota post-MTT

Trial Safety

Safety Progress

1 of 3

Other trials for Kidney Stones

Trial Design

3 Treatment Groups

Hypercalciuric Group
1 of 3
Hyperoxaluric group
1 of 3
Control group
1 of 3
Experimental Treatment
Non-Treatment Group

36 Total Participants · 3 Treatment Groups

Primary Treatment: Microbial Transplant Therapy · Has Placebo Group · Phase < 1

Hypercalciuric Group
Drug
Experimental Group · 1 Intervention: Microbial Transplant Therapy · Intervention Types: Drug
Hyperoxaluric group
Drug
Experimental Group · 1 Intervention: Microbial Transplant Therapy · Intervention Types: Drug
Control group
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: prior to fecal transplant (baseline)
Closest Location: Park City Hospital · Park City, UT
Photo of utah 1Photo of utah 2Photo of utah 3
2018First Recorded Clinical Trial
1 TrialsResearching Kidney Stones
1 CompletedClinical Trials

Who is running the clinical trial?

Litholink CorpUNKNOWN
University of MinnesotaOTHER
1,227 Previous Clinical Trials
1,454,367 Total Patients Enrolled
1 Trials studying Kidney Stones
53 Patients Enrolled for Kidney Stones
Albert Einstein College of MedicineOTHER
263 Previous Clinical Trials
1,838,691 Total Patients Enrolled
Joshua SternLead Sponsor
Joshua Stern, MDPrincipal InvestigatorIntermountain Health Care, Inc.
1 Previous Clinical Trials
140 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a medical history of urinary stone disease with >60% calcium oxalate stones.
You have a 24-hour urinary calcium concentration of 225 mg/day or urinary oxalate of 40 mg/day.
You are willing to undergo telephone follow-up to assess for safety and adverse events.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.